ARTICLES BY RAY SISON
-
CDMO Selection In Our Post-COVID World10/28/2022
In a post-pandemic world, we need to explore a broader view of our new reality. This article shares some of the concepts currently playing out in bio/pharmaceutical outsourcing that will impact your CDMO selection strategy. Additional discussion touches on how new outsourcing players will fit in and the path forward.
-
CDMO Selection: Can We Eliminate The On-Site Audit?12/15/2020
On-site capability assessments are an indispensable part of the CDMO selection process. But, due to travel restrictions brought about by the ongoing pandemic, supply chain professionals, as well as development and clinical stage biotech companies that outsource, have no choice but to rethink and re-evaluate this step of the process.
-
One-Stop Shop Or Best of Breed? 3 CDMO Selection Case Studies9/8/2020
Following last week’s editorial by chief editor, Louis Garguilo, Ray Sison, xCell Strategic Consulting, has prepared three case studies and a detailed analysis of the best-of-breed and one-stop-shop outsourcing models. Learn to define a strategy that best fits your product requirements and aligns with your corporate objectives.
-
2 Things Every Emerging Biopharma Needs To Know About Supply Chain5/8/2020
For clinicians on the front lines with potential effective therapies who are exploring how to develop new drug products, as well as development-stage companies looking to manage clinical supply chains and transform their organization for product launch, a basic framework is needed in order to integrate supply chain operation into a business strategy.
-
Negotiating Quality Technical Agreements: Strategies for Non-Quality Professionals8/20/2019
Of the four critical documents that must be negotiated and executed by both sponsor and CDMO (NDA, quotation, MSA/SA, and QTA), the QTA is often the least-prioritized by the procurement team. Yet, in practice, the QTA will be the most useful for development- and clinical-stage companies, because it provides a framework for operations and a road map for building quality systems.
-
How To Ace Your Next CDMO Capabilities Audit6/18/2019
Site visits require a significant investment of resources on the part of both a sponsor and its prospective CDMO, so swapping out the time required to prep, travel, meet, and follow up in favor of a two-hour teleconference is understandable … to a limited extent.
-
Early Formulation Development RFPs Made Easy11/20/2018
RFPs for early formulation development are different from tech transfers, clinical supplies, and other RFP strategies because the scope requirements need more flexibility to accommodate the unknowns of R&D.
-
3 Easy Questions Every Pharma Outsourcing RFP Should Answer7/10/2018
In pharma outsourcing, RFP templates are a time-saving and efficient tool to initiate and control a bidding process. They allow sponsors to collect comparable proposals that create leverage for negotiation.
-
CMO Selection: Are You Qualified?4/3/2018
Proactive companies and professionals tasked with procuring CMO services for difficult-to-place projects must become advocates to overcome barriers with a strategized approach and compelling narrative.
-
10 Simple Steps To Selecting The Right CMO11/28/2017
Contrary to how it sounds, controlling information is not about withholding key documents or facts that are relevant to the CMO bidding process to see how the bidders react, or only supplying pertinent information if requested. In fact, it is exactly the opposite is true.